期刊文献+

枸橼酸抗凝在持续缓慢低效血液透析中的应用 被引量:9

Evaluation of the application of regional citrate anticoagulation in sustained low efficiency hemodialysis
原文传递
导出
摘要 目的 通过对比持续缓慢低效血液透析(SLED)中局部枸橼酸抗凝与肝素抗凝的效果,为临床选择更优化的抗凝方式提供依据.方法 行SLED的63例急性肾损伤或终末期肾病患者,随机分为局部枸橼酸抗凝组和普通肝素抗凝组,均采用颈/股静脉留置双腔导管,费森尤斯公司生产的4008sARrTplus透析机和Polyflux 14L透析器,治疗时间8h,血流量150 ml/min.治疗前后测2组患者凝血酶原时间(PT)、APTT、PLT.结果 63例患者共行SLED治疗118例次,其中局部枸橼酸抗凝组行SLED枸橼酸抗凝56例次,普通肝素抗凝组行SLED肝素抗凝62例次.4例患者在住院期间因多器官功能衰竭死亡,余59例(93.7%)经SLED治疗后均好转出院或转为门诊规律血液透析.SLED 2 h时普通肝素抗凝组PT[(15.5 ±2.0)s]、APTT[(56.0±10.9)s]高于局部枸橼酸抗凝组[(12.3±2.7)s;(32.8±6.1)s],差异有统计学意义(P均<0.001).SLED 5 h时PT[(12.2 ±2.9)s比(12.2±2.5)s]、APTT[(33.7 ±6.6)s比(32.5±6.6)s]两组比较差异无统计学意义(P均>0.05).SLED治疗前后2组PLT差异无统计学意义(P均>0.05).结论 局部枸橼酸抗凝与普通肝素的抗凝效果相当,出血风险相对小,为临床医生提供了更多的SLED抗凝选择. Objective To compare the anticoagulation effect of regional citrate and heparin in patients with sustained low-efficiency hemodialysis (SLED).Method This study was conducted in the teaching hospital of Sichuan University between November 2011 and January 2013.Sixty-three patients suffering from acute kidney injury or end-stage renal diseases (ESRD) were enrolled and further randomized to 2 groups:citrate and heparin anticoagulation treatment groups in SLED.SLED was conducted by Fresenius 4008sARrTplus dialyzer for 8 hours each session,and blood flow was set at 150 ml/min.Prothrombin time (PT),activated partial thromboplastin time (APTT) and platelet (PLT) count were analyzed.Result Sixty-three patients underwent 118 sessions of SLED.Among them,59 patients (93.7%) was discharged after treatment or converted to outpatient intermittent hemodialysis,and 4 patients died of multiple organ failure during hospitalization.Compared with that in the citrate group,both PT and APTT in heparin group was significantly higher [PT:(15.5 ± 2.0) s vs (12.3 ± 2.7) s,P < 0.001 ; APTF:(56.0 ± 10.9) s vs (32.8 ± 6.1) s,P < 0.001 ; respectively] at 2 h during SLED.However,the PT and APTT levels in heparin group decreased afterwards and were similar with those in the citrate groups at 5 h during treatment.There is no difference on PLT counts between these two groups after treatment.Conclusion The anticoagulation effect of regional citrate and heparin was similar in patients when receiving SLED.Regional citrate may be an alternative anticoagulant approach for the patients at high risk of bleeding who require the treatment of SLED.
出处 《中华内科杂志》 CAS CSCD 北大核心 2014年第12期953-956,共4页 Chinese Journal of Internal Medicine
基金 “十二五”国家科技支撑计划(2011BAI10B08)
关键词 持续缓慢低效血液透析 枸橼酸 肝素 抗凝 无钙透析液 Sustained low efficiency dialysis Citrate Heparin Anticoagulation Calcium-free dialysate
  • 相关文献

参考文献19

  • 1付平,张凌.杂合肾脏替代治疗的临床应用[J].中国血液净化,2011,10(1):7-9. 被引量:22
  • 2Tolwani A J,Wheeler TS,Wille KM.Sustained low-efficiency dialysis[J].Contrib Nephrol,2007,156:320-324.
  • 3Kidney Disease:Improving Global Outcomes (KDIGO).KDIGO clinical practice guideline for acute kidney injury[J].Kidney Inter,2012,2 Suppl 1:1-138.
  • 4Wu MY,Hsu YH,Bai CH,et al.Regional citrate versus heparin anticoagulation for continuous renal replacement therapy:a metaanalysis of randomized controlled trials[J].Am J Kidney Dis,2012,59:810-811.
  • 5Fealy N,Baldwin I,Bellomo R.The effect of circuit "down-time" on uraemic control during continuous veno-venous haemofiltration[J].Crit Care Resusc,2002,4:266-270.
  • 6Tan HK,Baldwin I,Bellomo R.Continuous veno-venous hemofiltration without anticoagulation in high-risk patients[J].Intensive Care Med,2000,26:1652-1657.
  • 7Tolwani A J,Wille KM.Anticoagulation for continuous renal replacement therapy[J].Semin Dial,2009,22:141-145.
  • 8Hirsh J,Warkentin TE,Shaughnessy SG,et al.Heparin and low molecular-weight heparin:mechanisms of action,pharmacokinetics,dosing,monitoring,efficacy,and safety[J].Chest,2001,119(1 Suppl):64S-94S.
  • 9van de Wetering J,Westendorp RG,van der Hoeven JG,et al.Heparin use in continuous renal replacement procedures:the struggle between filter coagulation and patient hemorrhage[J].J Am Soc Nephrol,1996,7:145-150.
  • 10Clark JA,Schulman G,Golper TA.Safety and efficacy of regional citrate anticoagulation during 8-hour sustained low-efficiency dialvsis[J].Clin J Am Soc Nephrol,2008,3:736-742.

二级参考文献56

  • 1李洪,曾丽花,卢飞杏,吴洪兰,陈业珍,李德英,苏庆玲,赵英,黄烈诚.持续缓慢低效血液透析和连续静脉静脉血液滤过的对照研究[J].中华肾脏病杂志,2005,21(6):364-366. 被引量:26
  • 2Oudemans-van Straaten HM, Fiaccadori E, Baldwin I. Anticoagulation for renal replacement therapy : different methods to improve safety. Contrib Nephro, 2010,165:251-262.
  • 3Mariano F, Bergamo D, Gangemi EN, et al. Citrate anticoagulation for continuous renal replacement therapy in critically ill patients: success and limits. Int J Nephrol, 2011, 2011:748320.
  • 4Hetzel GR, Taskaya G, Sucker C, et al. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis, 2006, 48:806-811.
  • 5Tolwani A J, Wille KM. Anticoagulation for continuous renal replacement therapy. Semin Dial, 2009,22 : 141-145.
  • 6Hetzel GR, Schmitz M, Wissing H, et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofihration: a prospective randomized multicentre trial. Nephrol Dial Transplant, 2011,26 : 232-239.
  • 7Kutsogiannis DJ, Gibney RT, Stollery D, et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int, 2005,67:2361- 2367.
  • 8Monchi M, Berghmans D, Ledoux D, et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med, 2004,30:260- 265.
  • 9Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofihration. Crit Care Med, 2009,37:545-552.
  • 10Betjes MG, van Oosterom D, van Agteren M, et al. Regional citrate versus heparin anticoagulation during hemofihration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol, 2007,20 : 602-608.

共引文献75

同被引文献60

  • 1Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: intematlonal guidelines for management of severe sepsis and septic shock :2012 [ J]. Crit Care Med ,2013,41 (2) :580-637.
  • 2Oudemans-van Straaten HM, Kellum JA, Bellomo R. Clinical review :anticoagulation for continuous renal replacement therapy-heparin or citrate? [ J ]. Crit Care,2011,15 ( 1 ) :202-204.
  • 3Wang Y, Ivany JN, Perkovic V, et al. Anticoagulants and antiplatelet a- gents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease [ J ]. Cochrane Database Syst Rev,2016,6 ( 1 ) :67-71.
  • 4Fedotcheva NI, Litvinova EG, Osipov AA, et al. Influence of Microbi- al Metabolites of Phenolic Nature on the Activity of Mitochondrial En- zymes[ J]. Biofizika,2015,60(6) : 1118-1124.
  • 5Sponholz C, Matthes K, Rupp D, et al. Molecular adsorbent recirculat- ing system and single-pass albumin dialysis in liver failure--a pro- spective, randomised crossover study [ J ]. Crit Care,2016,4 ( 1 ) : 2- 6.
  • 6Hanafusa N. Application of continuous renal replacement therapy: what should we consider based on existing evidence? [ J]. Blood Pu- rif,2015,40(4) :312-319.
  • 7Liu J, Wang C, Zhao H, et al. Anticoagulant therapies versus heparin for the prevention of hemodialysis catheter-related complications : sys- tematic review and meta-analysis of prospective randomized controlled trials[J]. Int J Clin Exp Med,2015,15,8(8) :11985-11995.
  • 8Yorulmaz H, Ozkok E, Erguven M, et al. Effect of simvastatin on mi- tochondrial enzyme activities, ghrelin, hypoxia-inducible factor let in hepatic tissue during early phase of sepsis[ J]. Int J Clin Exp Med, 2015,8(3) :3640-3650.
  • 9Schmitz M, Heering PJ, Hutagalung R, et al. Treatment of acute renal failure in Germany: Analysis of current practice [ J ]. Med Klin Inten- sivmed Notfmed,2015,110(4) :256-263.
  • 10Schilder L,Nurmohamed SA,ter Wee PM,et al. Coagulation,Fibfinolysis and Inhibitors in Failing Filters During Continuous Venovenous Hemofil- tration in Critically Ill Patients with Acute Kidney Injury:Effect of Anti- coagulation Modalities[J]. Blood Purif,2015,39(4) :297-305.

引证文献9

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部